Canntab Engages Industry Leader Lorne Gertner as Consultant

Canntab Therapeutics Limited (CSE:PILL) (“Canntab” or the “Company”), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that it has engaged Lorne Gertner, one of the world’s foremost investors in the cannabis industry and one of its trailblazing pioneers, as a strategic consultant.  Mr. Gertner has significant experience on the boards of a number of publicly traded cannabis companies, including Hiku Brands Company, and has developed a global network of contacts in the cannabis industry along with a deep understanding of retail distribution, both of which Canntab hopes to leverage as it positions itself for expansion into international markets.

Mr. Gertner is a serial entrepreneur with experience in start-ups, IPOs, fashion, retail, architecture, real estate, and finance. Mr. Gertner is a co-founder and former chairman of PharmaCan Capital Corporation (MMJ.V), cofounder of Tokyo Smoke and the current Chairman of HG2 Capital Corp., an investment/merchant bank in the cannabis sector. Mr. Gertner is currently on the boards of Hiku Brands, and Green Acre Capital; he is also an adjunct professor at the John H. Daniels Faculty of Architecture, University of Toronto. Mr. Gertner is a graduate of The John H. Daniels Faculty of Architecture, University of Toronto and has completed the ICD.D designation at the Rotman School of Management, University of Toronto.

The Company will be compensating Mr. Gertner solely through the grant of 100,000 incentive stock options. Each such option entitles the holder thereof to acquire one common share for a period of 3 years at an exercise price of $1.00 per common share. Of the 100,000 options, 50,000 vest immediately, and the remaining 50,000 will vest in one year, provided that Mr. Gertner is still providing his services to the Company at that time.

Richard Goldstein, Chief Financial Officer of Canntab, stated, “Lorne Gertner is considered one of the godfathers of the industry, going back many years. He has been an advocate for medicinal cannabis use, and even supported a group of patients that had to face legal ramifications for using cannabis. He understood the benefits of medicinal cannabis long before it was permitted. He is a visionary and has developed a global network, which will allow assist Canntab in developing new business opportunities. The board of directors are very pleased that Mr. Gertner has agreed to become a consultant to the Company.”

Lorne Gertner added, “I’m so excited about working with Canntab, mainly because I strongly believe in management’s ability to execute, as Jeff has been in and around the pharmaceutical business his entire life and I believe the ultimate solution to the delivery of Cannabis will be through a hard pill. The problem with edibles today or infusion of any type is that they are combined with excessive sugar, and sugar is one of the killers in our society today. People today want something natural and our (Canntab) intention is to deliver a whole plant medicine through a hard tablet that is fast acting and long lasting.”

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For further information: Canntab Therapeutics Limited, Richard Goldstein, CFO, Office: 416 957-6303, Email: info@canntab.ca

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation.